TSPAN18 and cancer: Univariate analysis revealed that compared with patients with low TSPAN18 expression, patients with high TSPAN18 expression exhibited a more than twofold increase in the risk of mortality, especially cancer-specific deaths, in the two cohorts (OS: cohort 1, HR=2.35, 95% CI=1.21 to 4.54, p=0.011; cohort 2, HR=2.39, 95% CI=1.08 to 5.30, p=0.031; CSS: cohort 1, HR=2.77, 95% CI=1.18 to 6.59, p=0.019; cohort 2, HR=3.75, 95% CI=1.28 to 11.00, p=0.016; Supplemental table 4).